Astal Laboratories Ltd
Incorporated in 1993, Macro International Ltd used to export goods as well as sales through departmental stores. Presently, company is engaged in real estate business
- Market Cap ₹ 88.4 Cr.
- Current Price ₹ 82.0
- High / Low ₹ 103 / 66.7
- Stock P/E 8.92
- Book Value ₹ 40.5
- Dividend Yield 0.00 %
- ROCE 34.8 %
- ROE 30.1 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Company has delivered good profit growth of 213% CAGR over last 5 years
- Debtor days have improved from 246 to 157 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -1.74%
- Promoter holding is low: 18.2%
- Company has high debtors of 157 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 24 | 64 | 101 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 23 | 51 | 86 | |
| Operating Profit | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | -0 | -0 | 1 | 13 | 15 |
| OPM % | 10% | -4% | 5% | 20% | 14% | ||||||||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 0 | -0 | 0 | 1 | 12 | 13 |
| Tax % | 25% | -260% | 50% | 0% | 12% | 0% | 0% | 67% | 28% | 25% | |||
| 0 | 0 | 0 | 0 | -0 | -0 | -0 | 0 | -0 | 0 | 1 | 9 | 10 | |
| EPS in Rs | 0.23 | 0.45 | 0.03 | 0.03 | -0.03 | -0.20 | -0.08 | 0.03 | -0.05 | 0.05 | 0.79 | 9.08 | 9.85 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 115% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 48% |
| 5 Years: | 213% |
| 3 Years: | 665% |
| TTM: | 109% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 55% |
| 3 Years: | 50% |
| 1 Year: | 1% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 16% |
| 3 Years: | 20% |
| Last Year: | 30% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 10 | 10 | 11 |
| Reserves | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 26 | 33 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 13 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 13 | 14 | 44 | |
| Total Liabilities | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 10 | 37 | 63 | 101 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 11 | 11 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 10 | 36 | 52 | 89 | |
| Total Assets | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 10 | 37 | 63 | 101 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -1 | -6 | -13 | |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | -6 | -8 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18 | 3 | |
| Net Cash Flow | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 6 | -17 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0 | 337 | 244 | 157 | ||||||||
| Inventory Days | 0 | 18 | 112 | |||||||||
| Days Payable | 197 | 82 | ||||||||||
| Cash Conversion Cycle | 0 | 337 | 65 | 187 | ||||||||
| Working Capital Days | -73 | 138 | 118 | 97 | ||||||||
| ROCE % | 2% | 1% | 1% | 0% | 0% | -2% | -1% | 0% | 0% | 1% | 8% | 35% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
25 Nov - Received REACH certificate; Swiss LOI for 60 tonnes Piroctone Olamine, deliveries Dec 2025–Jun 2026.
-
Intimation Of REACH Compliance Certificate.
24 Nov - Received REACH compliance certificate (24-Nov-2025) enabling exports of speciality chemicals and advanced intermediates to EU.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 17 Nov
- Results- Financial Results For September 30, 2025 14 Nov
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Friday, 14Th November, 2025
14 Nov - Board approved unaudited Q2/H1 results ended 30 Sep 2025; Q2 revenue Rs 3,754.91L, Q2 PAT Rs 258.26L.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
Company used to have a departmental store at Kanpur and a saddlery export business. Company used to sell company bridles, halters, rugs, saddles, strip leather, reins, shoes and bell boots, etc. But due to unavoidable circumstances, business was closed down. Afterwards, company entered in real estate business.